Welcome to the 5th Annual QT Prolongation and Beyond
22nd –23rd November 2005, Le Meridien Piccadilly, London, UK
The recent agreements and implementation of the international clinical (ICH E14) guidelines will have significant impact on the pharmaceutical industry, forcing companies to reassess the development strategy of their drugs and their impact on cardiac repolarisation and the QT interval. This is likely to result in widespread application of thorough QT studies to assess the safety of drugs and questions the value and predictability of preclinical trials. In addition, more and more studies point to a genetic pre-disposition to QT prolongation, leading specialists to examine the possibility of preventing QT prolongation in sensitive patients. Finally, the recent changes have raised a cost issue throughout the industry leading to the issue of cost effective QT studies.
ViB events' 9th annual QT Prolongation and Beyond conference has been specifically designed to analyse in detail the preclinical and clinical guidelines and their impact on the industry as a whole. Leading experts in pre-clinical studies will assess the importance of pro-arrhythmic animal models and their worth for clinical trials. This timely and important event will also look at the numerous factors around the QT Prolongation issue such as congenital factors and other forms of acquired QT prolongation as well as addressing the implications of the S7 and E14 guidelines to costs now facing the industry.
